Sakamoto T, Harimoto K, Inoue S, Konishi A
Department of Traumatology and Critical Care Medicine, National Defense Medical College, Tokorozawa, Japan.
No To Shinkei. 1996 Sep;48(9):805-9.
The clinical effects were compared between a thrombolytic agent (urokinase) and a thromboxane synthetase inhibitor (sodium ozagrel) in patients with acute lacunar infarction. All patients had some degree of neurological deficits, which corresponded to the lesions on computerized tomography or magnetic resonance imaging. Urokinase of 420,000 units was given over two days in 11 patients, 160 mg/day of sodium ozagrel was administered for two weeks in 23 patients. The study was followed up to one month after the onset. Urokinase treatment improved motor paresis in 45.5-62.5% of the patients, sodium ozagrel in 68.4-86.7%. Using the combined score of motor paresis and conscious disorder, urokinase group revealed 44.4-45.5% improvement, but sodium ozagrel group 81.0-89.5% (p < 0.05). The rates of suppressive effect in progressing stroke and complete recovery were higher in sodium ozagrel group. Sodium ozagrel was clinically more efficient than urokinase in patients with lacunar infarction.
比较了溶栓剂（尿激酶）和血栓素合成酶抑制剂（奥扎格雷钠）对急性腔隙性脑梗死患者的临床疗效。所有患者均有一定程度的神经功能缺损，与计算机断层扫描或磁共振成像显示的病灶相符。11例患者在两天内给予420,000单位尿激酶，23例患者给予160毫克/天奥扎格雷钠，持续两周。研究随访至发病后一个月。尿激酶治疗使45.5%-62.5%的患者运动性轻瘫得到改善，奥扎格雷钠使68.4%-86.7%的患者得到改善。根据运动性轻瘫和意识障碍的综合评分，尿激酶组改善率为44.4%-45.5%，而奥扎格雷钠组为81.0%-89.5%（p<0.05）。奥扎格雷钠组进展性卒中的抑制率和完全恢复率更高。在腔隙性脑梗死患者中，奥扎格雷钠在临床上比尿激酶更有效。
